Table 2.
Baseline characteristics of patients who were administered andexanet alfa
| Variable name | Result |
|---|---|
| Number of patients | 21 |
| Age, years | 73.2 ± 15.4 |
| Male sex | 13 (61.9%) |
| Charlson Comorbity Index | 5 (3‐8) |
| Chronic kidney disease | 9 (42.9%) |
| Body mass index in kg/m2 | 26 [22‐31] |
| Prior venous thromboembolism | 6 (28.6%) |
| DOAC indication | |
| Atrial fibrillation | 16 (76.2%) |
| Recurrent popliteal thrombosis post‐bypass | 1 (4.8%) |
| Renal thrombosis | 1 (4.8%) |
| Recurrent deep venous thrombosis | 1 (4.8%) |
| Portal vein thrombosis | 1 (4.8%) |
| Superior vena cava occlusion | 1 (4.8%) |
| Factor Xa inhibitor type & dose | |
| Apixaban 2.5mg twice daily | 5 (23.8%) |
| Apixaban 5mg twice daily | 9 (42.9%) |
| Rivaroxaban 15mg daily | 1 (4.8%) |
| Rivaroxaban 20mg daily | 6 (28.6%) |
| Time since last dose of Factor Xa inhibitor | |
| <8 hours | 5 (23.8%) |
| 8‐18 hours | 11 (52.4%) |
| >18 hours | 3 (14.3%) |
| Unknown | 2 (9.5%) |
| Antiplatelet cotherapy | 8 (38.1%) |
| Primary source of bleeding | |
| Gastrointestinal | 5 (23.8%) |
| Intra‐abdominal | 5 (23.8%) |
| Intrathoracic | 4 (19.0%) |
| Retroperitoneal | 2 (9.5%) |
| Prevertebral | 2 (9.5%) |
| Thigh/groin hematoma | 2 (9.5%) |
| Cervical epidural | 1 (4.8%) |
| Visible bleeding | 5 (23.8%) |
| Traumatic injury | 5 (23.8%) |
| Presentation through ED | 19 (90.5%) |
| Bleeding during admission, after DOAC restart | 2 (9.5%) |
Data presented as median (interquartile range), mean ± standard deviation, or number (percent).
Abbreviations: DOAC, direct acting oral anticoagulant; ED, emergency department.